Introducing Risk Stratification Reduces Patient Burden and Improves Cost-Effectiveness of Hepatocellular Carcinoma Surveillance for People with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Modelling Study
Using a simple blood test to identify low-risk liver disease patients can substantially reduce unnecessary cancer screening, saving resources while maintaining safety in a growing population.
Using the Policy1-Liver model, this Australian study demonstrates that FIB-4 biomarker-guided risk stratification markedly improves HCC surveillance cost-effectiveness in the large MASLD population (~1/3 of Australians), with the highest-risk group (FIB-4 ≥2.67) achieving $15,055/QALY saved. Unstratified surveillance is wasteful in low-risk MASLD, underscoring the need for biomarker-driven precision surveillance as MASLD burden grows globally.
What the study was
- Study design
- decision_analytic_modelling
- Category
- precision_oncology
- Maturity
- Validated
- Journal
- Value in Health
Why it surfaced
MASLD-associated HCC is a growing surveillance challenge globally; FIB-4 stratification solution is immediately applicable and cost-effective evidence. Score 6 (N=2, D=1, P=2, E=1) reflecting strong unmet need but modelling-study design limitation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.